MetaCap

Armata Pharmaceuticals (ARMP) vs Humacyte (HUMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Armata Pharmaceuticals (ARMP) has outperformed Humacyte (HUMA) over the past year, losing 56.9% versus a loss of 63.5%. Over five years, ARMP leads with a -42.0% price change compared with -95.9% for HUMA. Humacyte is the larger company by market cap ($123.7 million vs $112.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%HUMA-63.49%
+120%+20%-80%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%HUMA-95.93%
+246%+67%-113%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus HUMA key metrics
MetricARMPHUMA
Share price$3.03$0.4454
Market cap$112.69M$123.73M
1-day change+1.68%-17.90%
YTD return-51.75%-53.65%
1-year return-56.90%-63.49%
5-year return-41.95%-95.94%
EPS (TTM)$-4.17$-0.45
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.04M
Net income (latest FY)$-173.80M$-40.83M
Gross margin—-376.05%
Operating margin—-5306.04%
Net margin—-2003.58%
52-week high$14.98$1.53
52-week low$2.40$0.337
Distance from 52-week high-79.77%-70.79%
Analyst consensusnonebuy
Avg. price target upside+477.56%+268.21%
Average volume182.52K5.36M
Shares outstanding37.19M277.80M
Employees61184
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Humacyte

HUMA stock →

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees

ARMP vs HUMA FAQ

Which is bigger, Armata Pharmaceuticals or Humacyte?

Humacyte (HUMA) is larger, with a market capitalization of $123.73M compared with $112.69M for Armata Pharmaceuticals (ARMP).

Which stock has performed better over the past year, ARMP or HUMA?

ARMP returned -56.90% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Humacyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons